# Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer

> **NCT01800422** · PHASE2 · UNKNOWN · sponsor: **Northwestern University** · enrollment: 50 (estimated)

## Conditions studied

- Stage IA Breast Cancer
- Stage IB Breast Cancer
- Stage II Breast Cancer

## Interventions

- **DRUG:** telapristone acetate
- **OTHER:** placebo
- **PROCEDURE:** therapeutic conventional surgery
- **OTHER:** laboratory biomarker analysis
- **OTHER:** questionnaire administration

## Key facts

- **NCT ID:** NCT01800422
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-06
- **Primary completion:** 2021-06
- **Final completion:** 2022-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-01-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01800422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01800422, "Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01800422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*